Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …

Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …

Nirmatrelvir (coadministered with ritonavir as PAXLOVIDTM) reduces the risk of COVID-19-
related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 …

Abstract Study Objective To estimate the prevalence of potential moderate to severe drug–
drug interactions (DDIs) involving nirmatrelvir/ritonavir, identify interacting medications, and …

We read with interest the Danish population-based study estimating the risk of significant
drug-drug interactions (DDIs) with the antiviral component, nirmatrelvir, of the drug …

Purpose Molnupiravir is an oral antiviral agent authorized for emergency use to treat mild to
moderate cases of coronavirus disease 2019 (COVID-19) in adults at high risk for …

Despite considerable progress in developing vaccines and antivirals to combat COVID-19,
the rapid mutations of the SARS-CoV-2 genome have limited the durability and efficacy of …

Ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme and is commonly used as
a pharmacokinetic (PK) enhancer in antiviral therapies because it increases bioavailability …

Background This study investigated the relationship between coronavirus disease 2019
(COVID-19), delirium, and 1-year mortality. Factors associated with delirium in COVID-19 …

COVID-19 antiviral medications approved or authorized for emergency use by the US Food
and Drug Administration are reported to have high efficacy in preventing severe illness …